Lipoprotein(a) Is an Independent Risk Factor for Peripheral Arterial Disease in Chinese Type 2 Diabetic Patients in Taiwan
- 1 February 2004
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 27 (2) , 517-521
- https://doi.org/10.2337/diacare.27.2.517
Abstract
OBJECTIVE—To examine the association between lipoprotein(a) [Lp(a)] and peripheral arterial disease (PAD) and determine the optimal cutoff in Chinese type 2 diabetic patients in Taiwan. RESEARCH DESIGN AND METHODS—Serum Lp(a) was determined in 557 type 2 diabetic patients (243 men and 314 women) recruited consecutively from a diabetes clinic at the National Taiwan University Hospital. Ankle-brachial index (ABI) n = 45) and n = 20). Potential confounders included age, sex, BMI, waist-to-hip ratio (WHR), diabetes duration, insulin usage, smoking, hypertension, systolic and diastolic blood pressure, fasting plasma glucose (FPG), total cholesterol, triglycerides, and HDL and LDL cholesterol. RESULTS—The distribution of Lp(a) was right skewed and no significant differences for sex, WHR, insulin usage, smoking, hypertension, and systolic and diastolic blood pressure were observed. In men, log[Lp(a)] was correlated positively with age, duration, and total and LDL cholesterol (borderline significant, P < 0.1) and negatively with BMI, triglycerides, and FPG (P < 0.1). In women, log[Lp(a)] was correlated positively with total and LDL cholesterol and negatively with triglycerides and BMI (P < 0.1). ABI was significantly correlated with log[Lp(a)], especially in men or in patients with PAD. The optimal cutoff determined by discriminant analysis was 13.3 mg/dl. Patients with Lp(a) above this value had a 2.7-fold higher risk of PAD after multivariate adjustment. Lp(a) also significantly increased from no PAD to mild and severe PAD (17.1 ± 14.4, 23.7 ± 20.3, and 36.9 ± 22.8 mg/dl, respectively, P < 0.001). CONCLUSIONS—Lp(a) is an independent risk factor for PAD in type 2 diabetic patients in Taiwan. The optimal cutoff is 13.3 mg/dl.Keywords
This publication has 24 references indexed in Scilit:
- A dose‐ranging study of a new, once‐daily, dual‐component drug product containing niacin extended‐release and lovastatinClinical Cardiology, 2003
- 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of HypertensionJournal Of Hypertension, 1999
- Dose-response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in TaiwanAtherosclerosis, 1996
- Lp(a) lipoprotein is an independent, discriminating risk factor for premature peripheral atherosclerosis among white menArchives of internal medicine (1960), 1994
- Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid Research Clinics Coronary Primary Prevention TrialJAMA, 1994
- Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based studyAtherosclerosis, 1994
- A prospective study of lipoprotein(a) and the risk of myocardial infarctionJAMA, 1993
- The Mysteries Of Lipoprotein(a)Science, 1989
- Lipoprotein(a) as a strong indicator for cerebrovascular disease.Stroke, 1986
- Lipoprotein Lp(a) and the risk for myocardial infarctionAtherosclerosis, 1981